Pirfenidone

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Hepatitis, KPMG, GNI, Cirrhosis, Patient, Chronic obstructive pulmonary disease, Sale, Coagulopathy, Ernst & Young, Idiopathic pulmonary fibrosis, Fibrosis, Therapy, COPD, Marketing, Partnership, Arthur Andersen, Audit committee, SAN, Safety, CVR, CHB, Fatty liver disease, Prevalence, Pharmacy, Hospital, Research, Acquisition, TGF, Pirfenidone, GAAP, Toxicity, Inflammation, Accounting, Entecavir, Loss, Orthostatic hypertension, IPF, Partner, NASH, Category 1, Pharmaceutical industry

Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.

Key Points: 
  • Mr. Nussbaum brings nearly four decades of experience in accounting and financial reporting in the U.S. and Asia Pacific Region.
  • In October 2023, Gyre (formerly known as Catalyst Biosciences, Inc. (“Catalyst”)) completed the previously announced business combination with GNI Group Ltd. (“GNI”) and related entities.
  • In October 2023, Gyre Pharmaceuticals completed enrollment of its Phase 3 trial in patients with CHB-associated liver fibrosis in the PRC.
  • Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.
    Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis Report 2023-2029: Enhancing R&D Operations for Development of Novel Treatments and Improving Access to Treatment - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Pharmaceutical, Health, Other Health, Prevalence, Market, Just Dance 2023 Edition, Porter's five forces analysis, Route of administration, Idiopathic pulmonary fibrosis, SWOT, IPF, Growth, Administration, Country, Pharmacy, Risk management, Nintedanib, Pirfenidone

The global market for idiopathic pulmonary fibrosis (IPF) is experiencing significant growth.

Key Points: 
  • The global market for idiopathic pulmonary fibrosis (IPF) is experiencing significant growth.
  • This recent market analysis report provides valuable insights into the IPF market, including historical data, current trends, and future projections.
  • The report thoroughly analyzes the IPF market based on its value in USD million.
  • As the prevalence of idiopathic pulmonary fibrosis continues to rise, this market analysis report serves as a valuable resource for healthcare professionals, researchers, and industry stakeholders.

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Retrieved on: 
Tuesday, September 26, 2023
Hydroxyproline, Tissue, Bleomycin, Lung, Fibrosis, TEL, Pulmonary fibrosis, Gold, Patent, CPA, Immunohistochemistry, Liver, IPF, Pharmaceutical industry, Pirfenidone

The approval of the patent in the US and the rest of the world is pending.

Key Points: 
  • The approval of the patent in the US and the rest of the world is pending.
  • With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until November 2037.
  • Previously, Galmed reported results showing significant anti-fibrotic effects of Aramchol in a pre-clinical model of lung fibrosis.
  • Treatment with Aramchol resulted in statistically significant fibrosis improvement in a validated bleomycin model of lung fibrosis (IPF), comparable to Pirfenidone which is the gold standard treatment.

Idiopathic Pulmonary Fibrosis Market - Global Growth Trends & Forecasts to 2028 - Rising Research and Development Activities in Fibrotic Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 21, 2023
Health, Pharmaceutical, Liminal, Idiopathic pulmonary fibrosis, Prevalence, COVID-19, Ageing, Research, Bristol Myers Squibb, USD, Boehringer Ingelheim, Pirfenidone, Incidence, Patient, Risk, Growth, Diagnosis, IPF, Disease, Pharmaceutical industry, Drug

The "Idiopathic Pulmonary Fibrosis Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Idiopathic Pulmonary Fibrosis Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's offering.
  • This growth is influenced by various factors, including the impact of the COVID-19 pandemic, increasing prevalence of IPF, a growing geriatric population, and significant research and development efforts in the field of fibrotic diseases.
  • The COVID-19 pandemic has played a significant role in shaping the IPF market.
  • Ongoing research and development activities and strategic initiatives by key market players, including product launches and collaborations, contribute to the growing adoption of pirfenidone.

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

Retrieved on: 
Thursday, May 25, 2023
Survival rate, Central nervous system, Depression, Psychosis, ATS, Survival, Bleomycin, Inflammation, CNS, Lung, Pulmonary fibrosis, Fibrosis, BLM, Food and Drug Administration Amendments Act of 2007, American Thoracic Society, HIV disease progression rates, International Conference on Conceptual Modeling, DSM-IV codes, Patient, Architecture, FDA, IPF, Relaxation, Conference, Idiopathic pulmonary fibrosis, Food, Pharmaceutical industry, Surveying, Brilaroxazine, Pirfenidone

CUPERTINO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis (IPF) at the 2023 American Thoracic Society (ATS) International Conference which took place in Washington, DC, USA, May 19-24, 2023. The Company also announced acceptance of this data for publication in Medical Research Archives. The ATS poster and online publication will be available at revivapharma.com/publications.

Key Points: 
  • The Company also announced acceptance of this data for publication in Medical Research Archives.
  • “This preclinical evaluation in IPF provides proof-of-concept support for the potential of brilaroxazine to treat pulmonary fibrosis and inflammation stemming from underlying dysfunction in serotonin signaling in the lung.
  • Brilaroxazine displays a high affinity and functional activity for the 5-HT2A/2B/7 receptors and moderate affinity for the serotonin transporter.
  • Brilaroxazine demonstrated efficacy with significant improvements in key endpoints in the bleomycin (BLM)-induced rat model of IPF.

PureTech Announces Annual Results for Year Ended December 31, 2022

Retrieved on: 
Friday, April 28, 2023
Health, FDA, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, PPD, Travel, Epilepsy, Survival, Head, Cmax, Audit committee, Patient, Investment, Financial management, Chair, Bone marrow, Annual general meeting, Therapy, Annual, BIIB, Attention, Salvatore LaMattina, Growth, IPF, GI, Anxiety, PRTC, BST, Pirfenidone, Safety, LSE, Interim, PureTech Health, Multimedia, Medicine, Acute myeloid leukemia, Fibrosis, Annual report, CBD, Chairperson, Form, Financial Conduct Authority, Tislelizumab, Bank statement, Clinical trial, DSM-IV codes, Woman, AGM, Inflammation, EDT, Sale, AML, Committee, Biogen, Cryptocurrency, Pharmaceutical industry, Management, Bank, Auction, DRS, EU, Proxy, Account

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter ended March 31, 2023.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter ended March 31, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230427006063/en/
    Members of the PureTech management team will host a conference call at 9:00am EDT / 2:00pm BST today, April 28, 2022, to discuss these results.
  • PureTech Health today released its Annual Report for the year ended December 31, 2022.
  • Annual Report and Accounts for the year ended December 31, 2022; and
    Notice of 2023 Annual General Meeting.

Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations

Retrieved on: 
Monday, April 10, 2023
Citadel, DevOps, University, Military, SCID, The Citadel, Sutro Biopharma, ICON, General partnership, University of South Carolina, Fanconi anemia, Master of Business Administration, MDS, Business administration, Darla Moore School of Business, Hardpan, Rituximab, CD117, ICON PLC, Therapy, Master, Pharmaceutical industry, Science, Takeda, Pirfenidone, Biology, Celecoxib, Jasper

REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company’s Senior Vice President, Development Operations.

Key Points: 
  • REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Company’s Senior Vice President, Development Operations.
  • His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our development programs for briquilimab,” said Ronald Martell, President and Chief Executive Officer of Jasper.
  • Previously he served as Vice President, Clinical Operations at PellePharm and Tioma Therapeutics.
  • He also led the clinical development and operations strategy at Alios Biopharma, Takeda, Clinipace, Exelixis, Kai Pharmaceuticals, Genentech, Genitope Corporation, and Intermune.

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

Retrieved on: 
Tuesday, January 31, 2023
Survival rate, Idiopathic pulmonary fibrosis, PRS, Idiopathic disease, Ophthalmology, IPF, Diagnosis, FastTrack, Development, US, Patient, CSP, Agent handling, Pharmaceutical industry, Pirfenidone, Daewoong Pharmaceutical

Under the terms of the agreement, Daewoong will grant CSP exclusive development and commercialization rights to Bersiporocin in IPF and other respiratory indications.

Key Points: 
  • Under the terms of the agreement, Daewoong will grant CSP exclusive development and commercialization rights to Bersiporocin in IPF and other respiratory indications.
  • Bersiporocin is a first-in-class antifibrotic agent that is being developed by Daewoong.
  • The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market.
  • Idiopathic Pulmonary Fibrosis is a rare, progressive lung disease in which thickening and hardening of lung tissues cause decline of lung function.

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Retrieved on: 
Thursday, January 19, 2023
ATyr Pharma, RNA transfection, Pirfenidone, European Patent Office, European Patent Convention, Lung, Biology, Interstitial lung disease, Idiopathic pulmonary fibrosis, Therapy, Patent, ILD, Research, Sarcoidosis, Fibrosis, SAN, Inflammation, EPO, HARS, IPF, N, Pharmaceutical industry

18 787408.6, titled, “Compositions and methods for treating lung inflammation,” covers the use of the company’s lead therapeutic candidate, efzofitimod, in combination with the anti-fibrotic agent pirfenidone.

Key Points: 
  • 18 787408.6, titled, “Compositions and methods for treating lung inflammation,” covers the use of the company’s lead therapeutic candidate, efzofitimod, in combination with the anti-fibrotic agent pirfenidone.
  • A patent from the recently allowed application is expected to be issued in the coming months.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease.

Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan

Retrieved on: 
Thursday, February 2, 2023
Pulmonary fibrosis, Teaching hospital, COVID-19, End organ damage, Chemokine, University Hospital of Basel, Pathology, RNA-Seq, PD, Lung, Patient, Idiopathic pulmonary fibrosis, FVC, Transfusion-related acute lung injury, Probability, IPF, KNRS, Pharmaceutical industry, Pirfenidone, Muthiri kinaru

Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • Kinarus Therapeutics AG (SIX:KNRS) “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced today preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis (IPF).
  • In a mouse model of lung injury, KIN001 significantly reduced lung weights and tissue fibrosis score vs. controls.
  • The combination of KIN001 with pirfenidone demonstrated greater reduction in lung fibrosis, indicating the potential for additional benefit of KIN001 in combination with the current standard of care.
  • KIN001 significantly reduced the upregulation of multiple key inflammatory cytokines and chemokines implicated in the pathology of lung fibrosis.